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Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative disorder that diverges from the process of normal brain aging by
unknown mechanisms. We analyzed the global structure of age- and disease-dependent gene expression patterns in three
regions from more than 600 brains. Gene expression variation could be almost completely explained by four transcriptional
biomarkers that we named BioAge (biological age), Alz (Alzheimer), Inflame (inflammation), and NdStress (neurodegen-
erative stress). BioAge captures the first principal component of variation and includes genes statistically associated with
neuronal loss, glial activation, and lipid metabolism. Normally BioAge increases with chronological age, but in AD it is
prematurely expressed as if some of the subjects were 140 years old. A component of BioAge, Lipa, contains the AD risk
factor APOE and reflects an apparent early disturbance in lipid metabolism. The rate of biological aging in AD patients,
which cannot be explained by BioAge, is associated instead with NdStress, which includes genes related to protein folding
and metabolism. Inflame, comprised of inflammatory cytokines and microglial genes, is broadly activated and appears early
in the disease process. In contrast, the disease-specific biomarker Alz was selectively present only in the affected areas of the
AD brain, appears later in pathogenesis, and is enriched in genes associated with the signaling and cell adhesion changes
during the epithelial to mesenchymal (EMT) transition. Together these biomarkers provide detailed description of the aging
process and its contribution to Alzheimer’s disease progression.
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Introduction
During normal aging the brain undergoes many changes
resulting in a gradual but detectable cognitive decline that is
associated with limited neuronal loss, glial proliferation in the
cortex, and gross weight decrease of 2–3% per decade [1,2]. On
the molecular level, the mechanisms driving aging of the brain are
not yet understood, but likely include mitochondrial DNA damage
[3] and chronic oxidative stress [4]. This slow decline in cognitive
ability does not interfere with normal function through at least 100
years of life. In contrast, Alzheimer’s disease (AD) is a debilitating
neurodegenerative disorder associated with a rapid cognitive
decline with an average survival of 5–10 years after the diagnosis
[5,6,7]. Age is the main AD risk factor with almost half of the
population over age 85 affected. AD, however, clearly differs from
the normal aging in that it causes dramatic loss of synapses,
neurons and brain activity in specific anatomical regions, and
results in massive atrophy and gliosis [1,8].
The factors that cause some individuals to depart from the
relatively benign process of normal brain aging and instead
undergo the pathological cascade that leads to AD are unknown.
A number of genetic risk factors for AD have been proposed
[9,10,11,12], however only the apolipoprotein E (APOE) e4-allele,
which lowers the age of onset and accelerates the cognitive decline,
has a large effect [13,14]. Pathologically AD is characterized by
the presence of two insoluble protein aggregates, senile plaques
formed from the peptide b-amyloid (Ab) and neurofibrillary
tangles composed of hyperphosphorylated tau protein [15]. In rare
familial AD, the cause of disease is autosomal dominant mutations
in Ab precursor protein (APP) or the Ab-producing enzymes
presenilins (PSEN1 or PSEN2), which are all thought to lead to
increased levels of aggregated Ab [9,10,16]. Likewise, mutations in
tau (MAPT) that predispose it to aggregation can cause specific
diseases that involve profound neurodegeneration and dementia
[17,18]. Thus, like in other neurodegenerative diseases such as
Huntington’s disease (HD) and Parkinson’s disease, the formation
of toxic insoluble aggregates seems to be a key pathogenic step.
However, it is not known why these Ab and tau aggregates
accumulate in AD patients nor how they contribute to neuronal
dysfunction, particularly for Ab deposits, which can often be found
in the brains of elderly non-demented subjects [19].
An important goal of AD research is to identify interventions
that maintain brain function, potentially by inhibiting the
formation or improving the clearance of neurotoxic aggregates,
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number of biological processes have been associated with AD,
including cholesterol metabolism, inflammation, and response to
misfolded proteins such as increased expression of heat shock
proteins [20]. The link with lipid metabolism is supported for
example by the essential role of APOE in lipid transport in the
brain [13,14]. However, these processes have not been unequiv-
ocally ordered into a pathogenic cascade, and the molecular
mediators and correlates of each are largely unknown. Microarray
gene expression profiling provides an opportunity to observe
processes that are common for normal aging, AD, and other
neurodegenerative diseases, as well as to detect the differences
between these conditions and disentangle their relationships. We
profiled over six hundred postmortem samples assembled in the
Harvard Brain Tissue Resource Center (HBTRC, McLean
Hospital, Belmont, MA). We used metagene (factor) analysis
[21,22,23,24,25] to distinguish several major gene expression
patterns involved in brain aging and disease and to quantitatively
define the corresponding biomarker scores. The correlation
analysis of the biomarker scores between three profiled brain
regions revealed systemic effects of the same disease processes on
different brain regions. We also propose a model of Alzheimer’s
disease progression that specifies the complex sequence of
molecular pathological events associated with the disease that
are driven by aging, which appears as the main factor in the
disease initiation and progression [1,8].
Methods
Study Population and Sample Collection
The dataset comprises gene expression data from brain tissues
that were posthumously collected from more than 600 individuals
with AD diagnosis, HD diagnosis, or with normal non-demented
brains. Allbrainswereobtained from individuals for whom both the
donor and the next of kin had completed the Harvard Brain Tissue
Resource Center Informed Consent (form available at: http://
www.brainbank.mclean.org/PDF files/Consent.pdf). All tissue and
research were conducted according to the Harvard Brain Tissue
Resource Center Guidelines (including: HUMAN TISSUE HAN-
DLING RISKS & SAFETY PRECAUTIONS agreement; HU-
MAN TISSUE SINGLE USER agreement, and HBTRC
ACKNOWLEDGMENT agreement, available at http://www.
brainbank.mclean.org/PDF files/TissueRequest.PDF). The study
was approved by McLean Hospital Institutional Review Board.
Braak stage [26] and atrophy were assessed by pathologists at
McLean Hospital (Belmont, MA). Only neuropathologically
confirmed AD subjects with Braak .3 were included in this
profiling experiment. The profiled brain regions included
dorsolateral prefrontal cortex (PFC, Brodmann area 9), visual
cortex (VC, Brodmann area 17), and cerebellum (CR). These
regions were chosen because PFC is impacted by the AD
pathology while the latter two regions remain largely intact
throughout most of the disease [26]. The tissue samples from
subjects with HD diagnosis, while not the main focus of this work,
were included to compare the two neurodegenerative diseases.
The samples were flash frozen in liquid nitrogen vapor with an
average postmortem interval (PMI) of about 18 hours. The clinical
and demographic information for this study, including diagnosis,
gender, age at the time of death, PMI, and Braak stage, is
summarized in Table S1.
Gene Expression Profiling
A total of 1 mg of mRNA extracted from each tissue sample was
amplified to fluorescently labeled cRNA, and profiled by the
Rosetta Gene Expression Laboratory in two phases using the
Rosetta/Merck 44k 1.1 microarray (GPL4372) (Agilent Technol-
ogies, Santa Clara, CA) [27]. The average RNA integrity number
of 6.81 was sufficiently high for the microarray experiment
monitoring 40,638 transcripts representing more than 31,000
unique genes. The expression levels were processed and
normalized to the average of all samples in the batch from the
same region using Rosetta Resolver (Rosetta Biosoftware, Seattle,
WA).
We refer to each batch of tissue samples using the abbreviated
brain region and the phase of the experiment (e.g., PFC2 refers to
prefrontal cortex samples profiled in phase 2). Table S1
summarizes the number of samples in each category. All
microarray data generated in this study are available through
the National Brain Databank at the Harvard Brain Tissue
Resource Center (http://national_databank.mclean.harvard.
edu/brainbank/Main). Any researcher wishing to obtain the de-
identified dataset can do so by contacting the National Brain
Databank at McLean Hospital, Harvard Medical School.
This microarray dataset is MIAME compliant. The raw and
final processed data for each hybridization are available to any
researcher upon request. The essential sample annotation
including experimental factors and their values (e.g., gender,
age, PMI, pH) is available and summarized in Table S1. The study
utilized a standard annotated microarray (GPL4372) and standard
pipeline of data processing for this array.
Data Analysis
We used the log10-ratio of the individual microarray intensities
to the average intensities of all samples from the same brain region
profiled in the same phase as the primary measure of gene
expression. Quality control of gene expression data was performed
by principal component analysis using MATLAB R2007a (Math-
works Inc., Natick, MA). Outlier samples (less than 2%) were
removed from the data set based on extreme standardized values
of the first, second, or third principal components, with absolute z-
scores more than 3.
The first principal component (PC1) was used to assess the
major pattern of gene expression variability in the dataset. Genes
that were highly correlated with PC1 were used to build a
surrogate biomarker. Throughout this work we used Pearson
correlation coefficients, r, and assessed their significance, p,
assuming normal distribution for Fisher z-transformed values,
atanh r [28]. Significant differential expression for each gene was
evaluated using t-test p-values [28]. Multiple-testing correction of
p-values was done according to Benjamini-Hochberg procedure to
obtain false-discovery rates (FDR) [29]. These analyses were
performed using Statistical Toolbox of MATLAB R2007a
(Mathworks Inc. Natick, MA).
Gene expression changes associated with aging and disease were
characterized by metagenes combining sets of genes with
significant association with a disease trait and a very strong
Pearson correlation with each other. We utilized a procedure of
exploring covariance structure of the gene expression data similar
to metagene identification [22], factor analysis of gene expression
[23], and supervised gene module discovery [21,24,25]. Instead of
genome-wide search for metagenes followed by analysis of
associations between metagenes and disease traits, we used a
supervised approach. After selecting genes significantly associated
with the disease, we agglomeratively clustered them using Pearson
correlation as a distance measure. Especially tight and large
clusters in the dendrogram were then assigned to metagenes, i.e.,
the dendrogram was cut so that several hundred genes in a branch
qualified for a metagene and the average of their correlations to
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that some metagenes could have two anti-correlated arms
representing opposite trends in the gene expression (e.g., genes
that are up- and downregulated with the end point).
The biological nature of the metagenes was assessed using the
gene set overlap analysis with known biological processes
described in GeneGo or Ingenuity. Significance of the overlaps
between the lists was assessed using Bonferroni-corrected p-values
[28], using Merck’s proprietary Target and Gene Information
system.
Biomarker Scoring
Throughout this work we adopted the term biomarker to refer to
a metagene together with associated score that quantifies it in each
brain tissue sample. The biomarker score for each sample was
calculated as the mean expression levels of the comprising gene
probes or as the arithmetic difference between the means in the
positive and negative arms of the metagene when both arms were
specified.
Score~ log
I
I0 UP
{ log
I
I0 DOWN
where I/I0 is normalized intensity of the metagene probes. To
produce a robust score, all samples have to be normalized to the
same reference. The reference intensity I0 for each gene
corresponded to the average intensity in the cohort. Importantly,
averaging genes that correlate with each other produced a
measure that is more accurate than individual genes. For all
metagenes identified in this work, the biomarker score represented
a quantitative measure of a particular disease aspect in each brain
sample. To evaluate the performance of the biomarker score as a
classifier between diseased and normal samples, we used the area
under the curve for the receiver operating characteristic (AUROC)
[30].
In Silico Experiments
To validate biomarkers identified in this work, we tested their
coherence and predictive power in the context of independent
gene expression dataset, GSE1572 [3]. This data set contained
gene expression data from PFC samples of 30 non-demented
subjects, aged 26–106. These samples were profiled on Affymetrix
Human Genome U95 Version 2 Array (GPL8300). To select the
probes and calculate the biomarker score, we matched the
biomarker gene symbols to those represented on the HG-
U95Av2 array. We calculated the correlation of the expression
level of each selected probeset with the composite biomarker score
(see above) and refined the selection by dropping probes that
demonstrated opposite regulation according to the sign of the
correlation coefficient. Finally, we correlated the biomarker scores
with the subject age.
An additional set of public gene expression data used to validate
the coherence and predictive power of the biomarkers was
obtained from hippocampus samples from elderly control and AD
subjects, GSE1297 [31,32]. These 31 samples were profiled using
Affymetrix Human Genome U133A Array (HG-U133A). To
select the probes and calculate the biomarker score, we matched
the biomarker gene symbols to those represented on the array,
refined them as described above, and averaged the gene
expression values according to the equation in the previous
subsection. The biomarker scores were then correlated with
MMSE (MiniMental State Examination) as an available measure
of AD severity.
Results
Biological Age
Analysis of differential gene expression in prefrontal cortex
samples between non-demented individuals and AD patients
revealed massive changes, with more than 18,000 transcripts
significantly regulated (ANOVA p,1E–6) by more than 28% (see
Fig. S1). Much of this differential expression was due to a single
gene expression pattern that defined the first principal component
(PC1) in both AD and normal samples. PC1 explained 45% of
variance in the upregulated genes and 60% of variance in the
downregulated genes. As shown on the heat map in Figure 1, AD
and normal samples dominated the opposite ends of this gene
expression pattern, with some subjects from each group in the
intermediate range. When normal and AD subjects were
considered separately, it was largely the same genes that
contributed to the PC1 pattern in both AD and normal samples
as shown by correlation analysis in Figure S1. This analysis
indicated that the same major biological process reflected in the
gene expression started in normal brains and continued develop-
ing in AD brains. We found a significant correlation of PC1 with
chronological age in non-demented individuals (r=0.58, p=9E–
13) and concluded that this gene expression pattern captures
normal aging processes in prefrontal cortex. Interestingly, this
correlation did not exist in AD patients (r=0.10, p=0.17). Table
S2 contains the lists of genes that were most up- and
downregulated with age and were selected based on the strongest
absolute correlations with PC1.
It is useful to ascribe a score based on average expression levels
of all included genes as a composite measure (see Methods). We
refer to the PC1 biomarker score as BioAge (biological age) based
on the hypothesis that the BioAge score for an individual is a more
precise and objective measure of the progression of age-related
changes than chronological age. Overall, most AD samples
attained much larger values of BioAge than normal samples
(AUROC=0.92). See also Table 1 for other characteristics of this
biomarker. Comparison of BioAge in AD and non-demented
individuals at different chronological age groups revealed a very
significant difference at younger ages which decreased in
chronologically older age groups. While BioAge of non-demented
individuals gradually increased with age, AD patients showed
consistently high levels of BioAge regardless of chronological age
(Fig. 2A). The extrapolated BioAge of normal subjects would reach
average AD levels at the age of 100 years. The most advanced AD
brains correspond to an extrapolated age of 140 years in non-
demented subjects.
As an independent test of the power of BioAge to predict
normal chronological age, we applied this biomarker to an
independent cohort of prefrontal cortex samples from non-
demented individuals (GSE1572). This gene expression data were
used to qualitatively describe aging in an earlier study [3]. BioAge
score in these samples strongly and significantly correlated with
chronological age of the subjects in the range from 26 to 106 years
(r=0.75, p=8E–7) (Fig. 2B). In addition, BioAge corresponded to
the second principal component in the GSE1572 dataset (r=0.90,
p=4E–11), validating that aging is a major reproducible source of
variance in gene expression in PFC. Similar prediction of
chronological age using gene expression was recently proposed
[33].
We performed another validation of BioAge as a predictive
biomarker of the brain condition in elderly subjects both with and
without AD using publicly available gene expression data from
hippocampus samples (GSE1297). These data were used in prior
research to qualitatively describe AD progression based on gene
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through severe AD [31,32]. We found that BioAge score
calculated in these samples strongly and significantly correlated
with the MiniMental Status Examination (MMSE) (r=20.59,
p=4E–4). Figure S2A demonstrates the association between
BioAge and AD severity. BioAge corresponded to the first
principal component in this data set (r=0.70, p=1E–5), capturing
a major source of gene expression variance and an overall brain
condition.
The massive gene expression changes associated with aging that
we detected involved a constellation of biological processes. A gene
set annotation analysis revealed that the genes downregulated with
increasing BioAge showed significant enrichment for neuronal and
synaptic processes, possibly reflecting neuronal depletion or loss of
plasticity (Table S3). The upregulated processes include lipid
metabolism, FAK signaling and axon guidance as well as the glial
marker, GFAP (Table S3). In agreement with an earlier analysis of
aging signatures observed in normal brains [2,3], the upregulated
genes contain several oncogenes (TP53, PI3K, PTEN, etc.), shown
to be strongly correlated with BioAge in Figure S3.
We also noticed that the genes upregulated with age in normal
samples could be further dissected using a metagene discovery
approach (see Methods). We focused on the normal samples with
relatively low BioAge (BioAge,0) and found a large metagene
with exceptionally high mutual correlation between the genes. We
named this metagene Lipa because it included APOE, PPARA, c-
protocadherins, and other genes involved in lipid metabolism,
amino acid metabolism and cell adhesion. Other notable Lipa
genes included HES1, TGFB2, NTRK2, and WIF1. This metagene
was much more coherent in normal samples than in AD samples.
The corresponding Lipa biomarker indicated an average 3-fold
upregulation of these genes early in the aging process. Figure S4
further illustrates the relationships between metagene-based
biomarkers and selected component genes mentioned in the text.
Figure 1. Gene expression in PFC1. The heat map shows hierarchical clustering of the 4000 most variable genes. The samples (rows) are sorted
according to the values of the first principal component of the complete dataset and labeled according to diagnosis (normal samples in black, AD
samples in red on the right).
doi:10.1371/journal.pone.0029610.g001
Table 1. Biomarker Characteristics.
Biomarker BioAge Inflame NdStress Alz
Differential variance explained, all samples 0.42 0.23 0.29 0.17
Differential variance explained, BioAge-matched samples 0.09 0.11 0.22 0.06
Coherence in normal samples 0.80 0.80 0.57 0.64
Coherence in AD samples 0.84 0.82 0.76 0.81
AUROC, all samples 0.92 0.88 0.89 0.81
AUROC, BioAge-matched samples 0.69 0.72 0.75 0.69
AUROC, normal and AD samples from PFC2 0.94 0.89 0.87 0.84
The reported values were obtained using PFC1 samples unless otherwise noted.
doi:10.1371/journal.pone.0029610.t001
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Higher BioAge of AD patients explained more than 50% of the
differential expression between normal and AD cohorts. In the
range of BioAge scores in which AD and normal individuals
overlap, there was a significant residual differential expression,
composed of several distinct subpatterns that explain a large
fraction of the normal-to-AD variance. We focused on 88 AD and
43 normal brain samples with matched moderate levels of BioAge
between 20.1 and 0.3. We identified 625 genes that are
differentially expressed between the two cohorts (ANOVA
p,0.005, absolute fold change .25%, FDR,0.1). Figure 3A
shows the supervised metagene analysis of these genes based on
clustering using gene-gene correlation as a distance measure (see
Methods). In this analysis we identified the 3 most regulated
metagenes responsible for the majority of the gene expression
differences associated with the disease.
The first and the largest group of about 2000 genes, further
referred to as NdStress, was associated with various metabolic
disruptions. This metagene contained some genes that were
upregulated and others that were downregulated in AD samples.
In normal brain samples with BioAge,0, the expression of these
genes was maintained in a relatively stable narrow range with
relatively low coherence. In AD samples, however, the expression of
these genes varied dramatically and was highly correlated (Fig. 3).
Although the plethora of biological pathways reflected in this large
metagene precluded significant enrichment of an individual
pathway after correcting for multiple testing, the upregulated arm
of this metagene contains multiple heatshock and proteosome
proteins such as HSP1A1, STIP1, HSP1B1, PSMB1/D6, and the
TGFb signaling proteins SMAD2 and SMAD4. The downregulated
arm of NdStress is enriched in genes involved in folate metabolism,
suchas DHFRL1, MTR and FPGS, possibly related to the alterations
in folate and homocysteine observed in AD patients [34,35,36]
(Table 2, S2, Fig. S4). Figure 4 includes the relationship between
NdStress and BioAge, which moderately correlated in AD samples
(r=0.53, p,1E–13). At the same time, NdStress and chronological
age correlated negatively (r=20.14, p=0.05). This biomarker
score explained 22% of variance in differentially expressed genes
and demonstrated AUROC of 0.75 in separating AD and normal
samples. See Table 1 for other biomarker characteristics.
The second metagene, further referred to as Alz, consisted of
about 200 genes upregulated in AD (Fig. 3). This metagene is
enriched ingenes involved in cell communication/adhesion,fibrosis,
mesoderm development and ossification such as numerous collagen
genes, BMP genes, CTSK, MFAP2/4, FN1, VIM, WNT6 and
TWIST1(Table2,S2,Fig.S4).Thismetagenealsocontainedseveral
prostaglandin synthases and receptors. Alz positively correlated with
both BioAge (r=0.40, p,1E–7) and chronological age (r=0.23,
p=0.002), see also Figure 4. This biomarker score explained 6% of
variance in differentially expressed genes and demonstrated
AUROC of 0.69 in separating AD and normal samples (Table 1).
Finally, a small but exceptionally tightly correlated metagene,
called Inflame (Fig. 3), contained about 250 genes upregulated
with AD, including many inflammation markers, such as IL1B,
IL10, IL16, IL18, and HLA genes, as well as markers of
macrophages, such as VSIG4, SLC11A1, and apoptosis, such as
CASP1/4, TNFRSF1B (p75 death receptor) (Table 2, S2, Fig. S4).
Inflame score explained 11% of variance in differentially expressed
genes and positively correlated with BioAge (r=0.47, p=1E–10)
and chronological age (r=0.28, p,0.001) in AD samples. When
used as a classifier, the Inflame score was capable of discriminating
AD and normal brain with AUROC of 0.69. These genes
maintained their mutual correlation in both normal and AD
samples but reached significantly higher levels in AD (Table 1).
Figure 4 shows the interplay between the biomarkers discussed
above and the complex causal relationships between them. For
example, the elevation of Inflame preceded the elevation of
NdStress because there are no samples with high NdStress but low
Inflame. The correlation between NdStress and Inflame is,
however, low in AD samples where NdStress is active (r=0.21,
p=0.004). We also observed a low correlation between NdStress
and Alz (r=0.21, p=0.004) and moderate correlation between
Alz and Inflame (r=0.47, p=1E–11) in AD samples.
We tested performance of these biomarkers in the public gene
expression data from hippocampus samples from elder non-
demented and AD subjects (GSE1297). We found that at least half
of genes in each of the biomarkers preserved their coherence. In
addition, we found that Alz was strongly elevated in 5 out of 7
severe cases of AD and correlated with MMSE (r=20.37,
p=0.04). Figure S2B shows the distribution of Alz scores among
Figure 2. Aging score versus chronological age in PFC1. The box plots (A) demonstrate the distribution of BioAge in different 5-year long age
segments and list the ANOVA p-values for the BioAge separation between normal and AD subjects in each chronological age segment. (B) Prediction
of chronological age in the independent normal cohort using BioAge. The postmortem prefrontal cortex samples from individual of different age
were profiled in an earlier study (GSE1572) [3]. BioAge was calculated based on average expression of several hundred genes from Table S2 (see
Methods).
doi:10.1371/journal.pone.0029610.g002
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significant association with MMSE.
Systemic and Localized Brain Changes
A unique feature of the HBTRC dataset is the availability of
tissue samples from different brain regions from the same
individual. All biomarkers in PFC were tested for coherence in
visual cortex (VC) and cerebellum (CR). We confirmed that
BioAge and the disease-specific biomarkers were also expressed
coherently and differentially between normal and AD samples. We
then performed direct correlation analysis between the biomarker
scores in these regions. BioAge demonstrated relatively high
correlations of 0.81 between VC1 and PFC1, with residual
differences possibly reflecting different levels of aging between the
brain regions. The Lipa biomarker also demonstrated high
correlation of 0.80 between these regions. We determined that
correlation between Inflame scores in PFC1 and VC1 was equal to
0.83. The highest correlation of 0.93 between PFC1 and VC1 was
observed in the NdStress biomarker. These results are also shown
in Figure 5, whereas similar observations for PFC1 and CR1 are
shown in Figure S5. This exceptionally high level of correlation
between the regions is likely explained by the systemic nature of
inflammation and metabolic regulation that span diverse brain
regions.
Alz scores, on the other hand, did not show any significant
correlations between regions in AD samples suggesting that this
biomarker is confined to affected brain regions [26] and more
specifically related to AD pathogenesis (Fig. 5, S5). Furthermore,
Figure 3. Disease-specific metagenes. (A) Clustered gene-gene correlation matrix demonstrating strong mutual correlations between genes that
were differentially expressed between AD and non-demented samples from PFC1. Three outlined clusters correspond to NdStress, Alz, and Inflame.
The coregulation of these genes is also shown in the panel (B). Each colored line represents expression levels of individual genes in 55 PFC1 samples
from non-demented and AD subjects sorted in the order of increasing BioAge. Only representative samples that scored in the top or bottom 3% for
any of the biomarkers were selected for this figure to improve visualization.
doi:10.1371/journal.pone.0029610.g003
Table 2. Selected pathways that are enriched in metagenes.
Biomarker Selected enriched pathways
Lipa Cell adhesion
**; RXR function
**; fatty acid metabolism
**; amino acid metabolism
**
(+) BioAge Molecular mechanisms of cancer
*; lipid metabolism
*; FAK signaling
*; axon guidance
*
(2) BioAge Neuronal activities
**, synaptic transmission
**; axonal guidance
*; long term potentiation/depression
**; molecular mechanisms of cancer
*;C a /
Glutamate/MAPK signaling
*
Inflame Innate immune response
**, apoptosis
**, macrophage
**
(+) NdStress Stress response
#; PPAR RXR acivation
#, glucocorticoid signaling
#
(2) NdStress Metabolic pathways
**; folate metabolism
#
Alz Cell communication
**; fibrosis
**; mesoderm development
**; cell adhesion
**; ossification
*
**Bonferroni corrected Hypergeometric p-value,0.05.
*Bonferroni corrected Hypergeometric p-value,0.1.
#Bonferroni corrected Hypergeometric p-value,0.5.
Up- and down regulated arms of metagenes are denoted as (+)a n d( 2). Complete analysis is shown in Table S3.
doi:10.1371/journal.pone.0029610.t002
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samples (Phase 2), which in addition contained some Huntington
disease (HD) samples. As shown in Figure S6, BioAge, NdStress,
and Inflame were significantly elevated in both AD and HD
samples (p,1E–6). In general, these biomarkers reached similar
average levels in AD and HD samples in all profiled brain regions.
In PFC2, however, the average BioAge reached in HD samples
was significantly lower than that of AD samples (p=1E–17). These
biomarkers, therefore, seemed to capture general systemic
neurodegenerative processes rather than being specific to AD.
The most striking difference between AD and HD samples was
reflected in the Alz biomarker, which again was specific to the
presence of AD was not significantly elevated in any brain region
in HD samples (Fig. 6).
Comparison with Brain Transcriptome Modules
Consistent patterns of gene coexpression were recently observed
in several large cohorts of brain samples from non-demented
individuals [24]. The authors discovered several reproducible
modules, which they called brain transcriptome modules, and
associated some of them with specific brain cell types. Particularly,
modules M4/5, M9, M15, and M16 were associated with
microglia, oligodendrocytes, astrocytes, and neurons, respectively.
We validated the coherence of these modules in the present
HBTRC dataset, and found that more than 90% of genes
comprising these modules strongly correlated with each other
(r.0.7) in non-demented subjects. This analysis supports the
finding that the latent structure of gene expression in cortex was
preserved in our dataset.
In addition, we compared the gene expression profiling
captured by the brain transcriptome modules with BioAge and
the other disease-specific biomarkers discovered here. We found a
strong correlation between M4/5, associated with microglia, and
our Inflame biomarker (r=0.92). In addition, ‘‘astrocytic’’ M15
positively correlates with BioAge (r=0.83) and ‘‘neuronal’’ M16
negatively correlates with it (r=20.93). We also found that none
of the major brain transcriptome modules strongly correlated with
either the neurodegenerative NdStress or AD-specific Alz
biomarkers. This confirms that these expression patterns are novel
patterns that can only be detected in brains affected by disease.
Discussion
Summary of Molecular Changes in AD
This genome-wide gene expression profiling study of a large
cohort of AD and normal aging brains revealed large groups of
genes that vary as a function of age and disease status. When the
hundreds of gene expression values contained in each of these sets
are converted into a single quantitative trait, new molecular
biomarkers of biological aging and disease progression emerge.
The transcriptional profiles of AD brains were profoundly
different from those in non-demented individuals, with thousands
of genes differing in their levels of expression between the two
cohorts. To reduce the complexity of the observed changes, we
focused on key gene expression patterns that explained the most
variability across the cohorts. We demonstrated that the most
significant pattern in terms of variance explained both within and
between AD and non-demented cohorts was BioAge, a biomarker
of the level of biological aging in the brain. BioAge captured the
extent of gradual molecular changes in the normal aging brain by
averaging the gene expression changes associated with a multitude
of synchronous physiological events. BioAge can be accurately and
reliably assigned to each brain tissue sample in the dataset and
used to describe the molecular state of the brain in the same way as
we use other clinical and physiological measurements.
Genes upregulated with BioAge point to activation of cell cycle
regulation pathways, lipid metabolism and axon guidance
pathways (Table S3). Misexpression of cell cycle genes in post-
mitotic neurons has been observed in aging and in AD and is
postulated to be an important mechanism of neurodegeneration
Figure 4. Plot matrix of mutual relationships between key aging and disease-specific biomarkers as well as chronological age. Each
biomarker is represented by its score in each sample based on the average gene expression of contributing genes (see Methods). Non-demented
PFC1 samples are shown by black dots. AD samples are shown by red dots. All pairwise relationships between the biomarkers and with chronological
age are shown.
doi:10.1371/journal.pone.0029610.g004
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with biological responses to genotoxic stress activated during aging
in an increasingly larger population of brain cells. Genes
downregulated with BioAge were associated with a decrease in
neuronal activity. Most of these genes maintained a strong
correlation (connectivity) with BioAge throughout the entire range
of the biomarker. This implies that the core of biological aging is
one gradual change rather than several distinct transitions.
Contrary to most aging patterns, a significant loss of
connectivity with aging was observed for the Lipa metagene that
included APOE, HES1, and TGFB2 (Fig. S4). APOE and most of
the other Lipa genes were expressed at high levels in all AD
patients and some normal individuals. This suggests that
upregulation of lipid metabolism happens sometime early in the
aging process and that activation of APOE and changes in lipid
metabolism are early precursors of disease possibly related to
engagement of protection mechanisms.
We also describe three other distinct disease-specific patterns.
The NdStress biomarker, which contained both up- and
downregulated genes, dominated differential expression between
AD and non-demented brains matched for BioAge score. The
upregulated genes contained multiple heatshock and proteasome
proteins. Activation of these pathways may reflect the response to
disease-related stress. Another set of genes in this module are cell
cycle genes indicative of cell cycle arrest or apoptosis. The
downregulated arm of NdStress is enriched in one-carbon/folate
metabolism genes and could underlay the perturbations in these
metabolic pathways, which are among the earliest biomarkers
associated with neurodegenerative disorders including AD
[34,35,36].
Figure 5. Correlation between biomarker scores in PFC1 and VC1 of the same individuals. Each plot shows relationships between the
biomarker values in PFC1 and VC1. Samples from non-demented and AD subjects are shown in black and red respectively.
doi:10.1371/journal.pone.0029610.g005
Figure 6. Comparison of NdStress and Alz in AD and HD. AD
samples of PFC2 are colored in red. HD samples are colored in
green. The reference biomarker scores corresponding to non demented
individuals are represented by dashed lines.
doi:10.1371/journal.pone.0029610.g006
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associated with cell adhesion, migration, and morphogenesis. This
metagene prominently featured genes characteristic of epithelial-
to-mesenchymal transition (EMT), such as VIM, TWIST1, and
FN1 [39], (Fig. S4). The connection of Alz with EMT suggests a
major transformation in brain tissue physiology including changes
in receptor signaling, growth factor dependence, and cell adhesion
during the disease. Considering that the third disease-specific
biomarker, Inflame, reflects chronic neuroinflammation [7,40], it
is hard to ignore the similarity between AD with other examples of
EMT type 2, such as tissue fibrosis, where chronic inflammation
and upregulation of TGFB2 contribute to pathogenesis [39]. The
levels of Alz in AD are much higher than in unaffected brain
regions or in the PFC in HD, suggesting that these gene expression
changes are not generally reflecting neurodegeneration, but relate
to AD pathology.
Finally, BioAge and Inflame are consistent with published
analysis of the healthy brain transcriptome and are associated with
neuronal, astrocytic, and microglial modules [24]. Importantly, we
found that NdStress and Inflame have virtually identical scores in
different regions from the same individual. It suggests they
measure systemic changes in brain tissue that happen across
multiple cell types and layers and are independent of the diverse
morphology and makeup of different brain regions. Alz scores, on
the other hand, are not the same across all brain regions and had
the highest levels in prefrontal cortex, indicating a local rather
than systemic nature of EMT.
Alzheimer Disease Progression Model
Our analysis of gene expression changes in the brains of
Alzheimer’s patients confirms that AD is both similar and distinct
from the process of normal aging. Although each brain was
captured only in a particular (postmortem) state and was not
studied longitudinally, we can assemble these data as a function of
time to propose a few generalized aging trajectories. BioAge and
chronological age showed a significant association in non-
demented individuals and no association in AD patients, who
had consistently high BioAge scores regardless of their chrono-
logical age. We attribute this observation to a difference in the
strength of the aging drivers, distribution of the aging rates, and
different causes of death in the two cohorts. In non-demented
individuals, the drivers of aging were weak; the rates of aging were
relatively slow and consistent across the population; and, in the
absence of unnatural causes, death was likely related to aging
issues other than the health of the brain. Since non-demented
individuals likely died from causes largely unrelated to neurode-
generation, each individual death is conceptually a random event
along the generalized brain aging trajectory. In AD patients, the
drivers of aging were stronger and variable across the cohort; and
death was generally related to the health of the brain that became
incompatible with life regardless of the chronological age. The
extrapolated BioAge of normal patients would not reach the
highest AD levels until the age of 140 years. Thus, AD can be
viewed as an aberrant aging of the brain, which retains the gene
expression hallmarks of normal aging combined with additional
patterns associated with pathological drivers of the disease and
response of the brain tissue to disease-related processes.
For AD patients, we are missing early stages of the aging
trajectory and observe only late stages with terminally high
BioAge. Unlike the normal cohort that can be represented by a
single trajectory, the AD cohort covers a family of trajectories with
different rates of biological aging. Patients with a fast rate of
biological aging would succumb to disease at younger ages and
generally would have higher levels of BioAge relative to their
chronological age in the early phases of disease. However, since we
do not have longitudinal specimens from subjects before they
develop the disease, a second biomarker is required to explain
disease progression rates after BioAge is maximal. The expression
profile of NdStress fits the properties expected of this progression
rate biomarker: it is highest in chronologically young AD patients,
and it significantly correlates with (+) BioAge and (2) chronolog-
ical age. Alz, on the other hand, is the highest in chronologically
older patients and does not correlate with BioAge. Thus, patients
with high NdStress likely have more accelerated aging trajectories
than patients with high Alz. The older chronological age of Alz
onset may suggest that the acceleration of BioAge due to Alz does
not occur until the level of BioAge of the brain reaches a certain
threshold. The quantitative assessment of the brain biological age
in terms of BioAge and the rate of its disease-related acceleration
in terms of NdStress are two critical hypotheses proposed in this
work.
Another way to look at the aging trajectory is to model it as a set
of molecular transitions that lead to changes in BioAge.
Examination of biomarker scores for BioAge-low brains in
Figure 4 suggests that upregulation and disruption of Lipa
biomarker happens very early in the aging process because most
of these samples have the lowest Lipa scores in the cohort.
Comparing Inflame with Lipa and BioAge shows that activation of
the inflammation biomarker also happens early in the aging
process, but not as early as Lipa activation, because there are
BioAge-young patients with high Lipa score yet low Inflame.
These and other observations can be summarized in the form of a
state transition model shown in Figure 7. Aging starts with
upregulation of APOE and other lipid metabolic genes together
with Notch and TGFb signaling, signifying the transition from N0
to N1. The following upregulation of the Inflame biomarker is
associated with transition from N1 to N2. The brains in these
states were diagnosed as normal because the subjects did not yet
exhibit any cognitive impairment associated with AD. The next
transition, from N2 to A1, is associated with massive disruptions in
metabolic pathways and marked acceleration of aging follows.
Some brains, however, avoid transitioning to A1 and continue to
age into N3. Another transition to AD state A2 can happen later,
since we observe brains with high scores for both NdStress and
Alz, which may be associated with a different path to AD.
Alternatively, A2 is possibly localized to a brain region not covered
in the dataset. This transition may, therefore, appear later than A1
in a particular brain region and happen much earlier in some
other brain region.
The proposed model is most consistent with an age-based
hypothesis of Alzheimer’s disease that postulates three fundamen-
tal steps: initial injury aggravated by age, chronic neuroinflamma-
tion, and transition of most brain cells to a new state [8]. These key
stages of the disease were independently observed and associated
with transcriptional changes in our analysis of the brain
transcriptome. We also identified a striking resemblance of the
biological processes behind the disease progression biomarkers
with epithelial-to-mesenchymal transition (EMT) [39]. The AD
processes are most similar to EMT type 2, which is dependent on
inflammation-inducing injuries for initiation and continued
occurrence. Associated with tissue regeneration and organ fibrosis
in kidney, lung, and liver, EMT type 2 generates mesenchymal
cells that produce excessive amounts of extracellular matrix
(ECM). Similarly, a transition of AD brain into a tissue enriched
with mesenchymal cells produces a large amount of ECM
containing b-amyloid. This model of the disease implies that
multiple independent genetic factors, as well as infections and/or
injuries may accelerate consecutive transitions leading to the
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and late disease stages. Therapies targeting lipid metabolism and
inflammation may be more effective in the early stages. In the late
stages, when the brain becomes enriched in mesenchymal-like
signaling and adhesion processes, novel approaches that support
the survival of the new state of the brain tissue should be
considered.
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Figure S1 Differential gene expression and variance in
PFC1. (A)Cumulative p-valuedistributioninthet-test betweenAD
and normal samples. The blue line shows the number of sequences
that can be detected for a given p-value cutoff. For example, at
p,1E–6, about 18,000 genes can be detected. The green line shows
the level of false positives due to multiple testing. (B) Pareto diagram
of variance explained by the first 10 principal components. The first
principal component dominates the distribution explaining 33% of
the data variance. (C) Comparison of correlations between PC1 and
individual genes in normal and AD samples. Related to Figure 1.
(PDF)
Figure S2 Validation of BioAge and Alz biomarkers in
GSE1297. Panel (A) demonstrates the relationships between
projected BioAge score and the disease severity as MMSE. The
points are colored according to the assigned severity level. The box
plots represent the distribution of the biomarker scores in the
hippocampus samples from non-demented control subjects and
subjects with AD of different severity. Panel (B) shows the same
analysis for the Alz biomarker.
(PDF)
Figure S3 Regulation of selected sell cycle regulation
genes with BioAge. The heat map shows hierarchical clustering
of selected 17 genes involved in cell cycle regulation and DNA
repair. The samples (rows) are sorted according to the values of the
first principal component of the complete dataset and labeled
according to diagnosis (normal samples in black, AD samples in
red on the right). Related to Figure 2.
(PDF)
Figure S4 Expression of selected genes and their
relationships with biomarkers. The heat map shows
hierarchical clustering of 17 selected genes and 5 biomarkers
developed in this work. The samples (rows) are sorted according to
the values of the first principal component of the complete dataset
and labeled according to diagnosis (normal samples in black, AD
samples in red on the right). Only samples with BioAge,0.4 are
shown. Related to Figure 3.
(PDF)
Figure S5 Correlation between biomarker scores be-
tween PFC1 and CR1 of the same individuals. Each plot
shows relationships between the biomarker values in PFC1 and
CR1. Samples from non-demented and AD subjects are shown in
black and red respectively. Related to Figure 5.
(PDF)
Figure S6 Validation of mutual relationships between
key biomarkers in PFC2 cohort, which contained non-
demented (black), AD (red), and HD (green) samples.
Compare with Figure 6.
(PDF)
Table S1 Demographic, clinical, and experimental
composition of the HBTRC gene expression dataset.
(PDF)
Table S2 Gene sets that comprise gene expression
biomarkers of aging and AD progression.
(XLS)
Table S3 Functional annotations of the biomarker gene
sets based on pathway enrichment. The abridged
summary of this analysis is provided in Table 2.
(XLS)
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Figure 7. Disease progression model. The trajectories of BioAge changes as a function of time reflect the relatively constant rate of aging in non-
demented subjects (black), and acceleration of the rate of aging in AD (red). The dots represent the postmortem state of the brain captured by gene
expression profiling. The state transition model defines several broad categories for normal brains N0–N3 and for diseased states A1 and A2. The
sequence of transitions and associated gene expression biomarkers are shown by arrows.
doi:10.1371/journal.pone.0029610.g007
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